- Trial Phase
- Phase 2
- Time to Market
- At least 3-5 years. Registration-directed (Phase 3) program expected to begin in H1 2027; typical Phase 3 + FDA review takes 3-4 years from initiation.
- Why 5/10
- The next catalyst is the planned initiation of a registration-directed (Phase 3) program in H1 2027, which is ~6-12 months out but is a program start, not a binary data readout. The big binary catalyst (Part B Phase 2a topline data) just fired on July 13, 2026, when positive 36-week results drove the stock ~60% higher in a single day. No PDUFA date or pivotal readout is currently scheduled. ImpactScore 5 reflects that bempikibart is Q32 Bio's sole remaining late-stage pipeline asset (after the ADX-097 sale) but lacks a hard, dated binary within ~6 months.
The July 13 positive Phase 2a data has already been priced in (~60% single-day surge). The next meaningful catalyst is the start of a Phase 3 registration program in H1 2027 — but that is a process milestone, not a binary event. Investors should watch for FDA feedback on the registration-directed plan, potential partnership interest given the clean safety profile, and additional financing rounds as Q32 Bio will need capital to fund the pivotal trials.
Price Chart
Executive Summary
Bempikibart (ADX-914) is Q32 Bio's lead — and after the ADX-097 sale, essentially sole late-stage — asset. It is a first-in-class anti-IL-7Rα antibody in Phase 2 development for alopecia areata (AA). On July 13, 2026, the company reported positive 36-week Part B data from the SIGNAL-AA trial showing a 35.3% mean reduction in the primary SALT severity score, 40% SALT-20 response rate, and a clean safety profile — driving a ~60% single-day stock surge. A prior Phase 2a trial in atopic dermatitis (SIGNAL-AD) failed its primary endpoint in December 2024. The company now plans a registration-directed (Phase 3) program beginning in H1 2027. Bempikibart competes against approved JAK inhibitors (Pfizer's Litfulo, Lilly's Olumiant) and other emerging biologics in the AA market, but its novel mechanism and clean safety profile (no black-box warnings like the JAK class) could differentiate it. The ~$190M market-cap company will need additional capital to fund the pivotal program.
How It Works
Bempikibart is a lab-made antibody (a type of protein) that blocks a specific receptor on immune cells called IL-7Rα. By blocking this receptor, it disrupts two inflammatory signals (IL-7 and TSLP) that drive autoimmune diseases. This effectively "re-regulates" the immune system — calming the overactive immune attack on hair follicles (in alopecia areata) or skin (in atopic dermatitis) — without broadly suppressing the entire immune system like traditional immunosuppressants.
Trial Status
Completed Part A (randomized, placebo-controlled) and Part B (open-label, 36-week) of the SIGNAL-AA Phase 2a trial in alopecia areata. Part B showed a 35.3% mean SALT reduction at Week 36 in the mITT population, with 40% achieving SALT-20 (≥80% scalp hair coverage) and no Grade 3+ adverse events. The SIGNAL-AD Phase 2a trial in atopic dermatitis failed its primary endpoint in Part B (Dec 2024). The company plans to advance into a registration-directed program in H1 2027.
The Two-Sided Case
Upcoming Catalysts
- Initiation of registration-directed (Phase 3) program in H1 2027 — expected after FDA engagement on trial design.
- Full Part B SIGNAL-AA results to be presented at a future medical meeting (date TBD).
- 52-week off-drug follow-up data from SIGNAL-AA Part B (ongoing).
- Open-label extension (OLE) data from SIGNAL-AA.
- Potential partnership or licensing interest from larger pharma given clean safety profile.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Q32 Bio Inc. 8-K QTTB ·Originating report